RxSight, which sells premium adjustable intraocular lenses used in cataract surgery, raised $118 million by offering 7.4 million shares at $16, the low end of the range of $16 to $18.
RxSight markets its RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens and the RxSight Light Delivery Device, to offers the first and only commercially available intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
RxSight plans to list on the Nasdaq under the symbol RXST. J.P. Morgan, BofA Securities, and SVB Leerink acted as joint bookrunners on the deal.
